Company news

Inovio Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

November 2, 2026

INOVIO to Participate in Upcoming Scientific Conferences

November 2, 2026

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

October 30, 2026

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

October 20, 2026

INOVIO to Participate in Upcoming Investor Conferences

September 1, 2026

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 12, 2026

INOVIO to Report Second Quarter Financial Results on August 12, 2026

August 4, 2026

INOVIO Announces Pricing of $20.0 Million Public Offering

July 29, 2026

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

May 21, 2026

INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026

INOVIO to Report First Quarter Financial Results on May 13, 2026

May 1, 2026

INOVIO Announces Pricing of $17.5 Million Public Offering

April 1, 2026

INOVIO to Participate in Upcoming Scientific Conference

April 1, 2026

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 12, 2026

INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

March 4, 2026

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

March 4, 2026

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

March 4, 2026

INOVIO to Participate in Upcoming Scientific and Investor Conferences

February 12, 2026

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

December 29, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

December 19, 2025

INOVIO to Participate in December Investor Conferences

November 18, 2025

INOVIO Announces Pricing of $25 Million Public Offering

November 11, 2025

INOVIO Announces Proposed Public Offering

November 10, 2025

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 10, 2025

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

November 3, 2025

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

October 27, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

October 23, 2025

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

October 21, 2025

INOVIO to Participate in Upcoming Scientific Conferences

September 25, 2025

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

August 26, 2025

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

August 25, 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 12, 2025

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

August 11, 2025

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

August 4, 2025

INOVIO to Present at Upcoming Scientific Conference

July 7, 2025

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

July 1, 2025

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 13, 2025

INOVIO to Present at Upcoming Scientific and Investor Conferences

April 30, 2025

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

April 29, 2025

INOVIO to Present at Upcoming Scientific Conferences

April 9, 2025

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

March 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

March 13, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

March 12, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

February 11, 2025

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

February 9, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 28, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

January 8, 2025

INOVIO Announces Pricing of $30 Million Public Offering

December 12, 2024

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

December 2, 2024

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 13, 2024

Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.